Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> AMGEN Latest News

JAN 26, 2013 - Benzinga

A Must Read - Share

Amgen Phase 3 Trial of Neulasta in Patients with Colorectal Cancer Met Primary Endpoint

Amgen (NASDAQ: AMGN) announced today results from Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES), a Phase 3 trial which evaluated Neulasta® (pegfilgrastim) in 845 patients receiving FOLFOX or FOLFIRI and bevacizumab for the first-line treatment of locally-advanced or metastatic colorectal cancer.

Tags: Amgen Phase 3 Trial of Neulasta in Patients with Colorectal Cancer Met Primary Endpoint,  Amgen Latest News